Healthcare and Life Sciences

Format: 2017-01-21
Format: 2017-01-21
January 03, 2017 | 95 Pages | SKU: IRTNTR11374

Overview of the global optical imaging market

The global optical imaging market is anticipated to grow at a steady rate and will post a CAGR of more than 8% during the forecast period. The increasing market penetration of digital technologies in the optical imaging and medical imaging areas will drive the growth prospects for the global optical imaging market over the next four years. According to the global market research, the application of laser technology includes optical imaging, medical imaging, and microscopy. Also, to increase the process efficiency, the optics and photonics technology is integrated to develop advanced optical imaging systems. Furthermore, the radiation-free Optical Coherence Tomography (OCT) technology is used for dental diagnosis and treatment, whereas, the sound navigation and ranging (SONAR) technology are used for capturing images as a part of digital technology in the medical imaging process.

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market until the end of 2021.         One of the major factors responsible for the increasing number of installations of optical imaging systems is the continual demand from North America that holds the largest market share in the region. Also, according to the industry research report, the adoption rate of optical imaging systems in the US clinics and operating rooms is witnessed to be very high. Moreover, the rate of adoption of these devices is high because they are cost-effectiveness and have non-invasive nature. Furthermore, the developing public-private partnerships would reduce the overall healthcare expenditure, which would boost the influx of end users and accelerate the market’s growth


January 02, 2017 | 115 Pages | SKU: IRTNTR11341

Overview of the global left atrial appendage (LAA) closure market

The global LAA closure market is anticipated to grow rapidly and post a CAGR of more than 33% during the forecast period. The increasing number of product approvals will drive the growth prospects for the global LAA closure market until the end of 2021. One of the major factors responsible for the increasing product approvals is the rising number of research activities by vendors. For instance, in March 2015, Boston Scientific received the US FDA approval of WATCHMAN device that consists of a catheter delivery system and is used to implant the device permanently in the LAA of the heart. Furthermore, in June 2016, AtriCure, received approval from the Ministry of Health, Labour and Welfare (MHLW) for its AtriClip products that include AtriClip Standard and the AtriClip Pro devices.

In terms of geography, EMEA accounted for the maximum market share in 2016 and will continue to dominate the market during the next few years. It has been observed that favorable guidelines for manufacturers and the increased awareness among physicians drives the adoption rate of LAA closure devices in the region. Also, the growing clinical trials produce high-quality data that further drives the adoption of LAA closure in EMEA.

Competitive landscape and key vendors

The global LAA closure market is in the nascent stage and has a presence of few key players that offer commercial products in the market. Since the market witnesses a stringent regulatory environment, new entrants find it difficult to enter the market.

Key vendors in this market are -

  • AtriCure
  • Boston Scientific
  • Coherex Medical
  • St. Jude Medical

Other prominent vendors in the market include Occlutech, Lifetech Scientific, and SentreHEART.

Segmentation by product


December 30, 2016 | 128 Pages | SKU: IRTNTR11316

Overview of the global protein therapeutics market

Market research analysts at Technavio predict that the global protein therapeutics market will grow steadily during the next four years and post a CAGR of almost 8% by 2021. This market research analysis identifies the increased demand for monoclonal antibodies (mAbs) as one of the primary growth factors for this market. mAbs accounts for a major share of protein therapeutics. The increasing usage of mAbs in various therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy will drive the growth of the market. Additionally, mAbs are also used in the formulation of biopharmaceutical drugs for the treatment of different diseases including cancer and ulcerative colitis which will also aid in the market’s growth in the coming years.

This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the market throughout the forecast period. Factors such as the increase in uptake of the existing protein therapeutics and the rise in approvals for certain formulations that will induce more vendors to conduct R&D activities and enter the market, will boost the market’s growth prospects in this region.  

Competitive landscape and key vendors

The market is highly competitive and consists of numerous small and large-scale vendors who operate at a local or global scale. To enhance their global reach and increase revenue shares, vendors have started forming strategic alliances to manufacture and market drugs. Companies engaged in manufacturing and marketing protein therapeutics that can effectively treat various disorders will gain a competitive edge over the other vendors in the market. The market’s growth


December 29, 2016 | 77 Pages | SKU: IRTNTR11320

Overview of the global chemotherapy-induced nausea and vomiting (CINV) drugs market

Market research analysts at Technavio predict that the global CINV drugs market will grow steadily during the next four years and post a CAGR of almost 6% by 2021. This market research analysis identifies the growing preference of chemotherapy in the developing countries across the globe as one of the primary growth factors for the chemotherapy-induced nausea and vomiting drugs market. Though the use of chemotherapy drugs in combination with other therapies will drive the demand in the developed countries, the coming years will still witness a decline in the preference for chemotherapy drugs in these regions. However, the increased preference toward chemotherapy for the treatment of cancer in the developing countries such as China and India will drive market growth since the demand for targeted therapies is still in the nascent phase in these countries. This will drive the demand for CINV drugs, consequently fuelling market growth.

To enhance their product portfolio and establish their market presence vendors will start following inorganic growth strategies such as acquisitions and alliances, which will allow market players to reduce their R&D costs and quickly penetrate into the market. For instance, Helsinn and Purdue Pharma Canada entered into an exclusive agreement for the distribution and licensing of the CINV drug Akynzeo. This enabled Helsinn to retain the clinical development, manufacturing, and commercialization of Akynzeo, whereas Purdue Pharma Canada gained the right to register, promote, and commercialize Akynzeo in Canada.

Competitive landscape and key vendors

The market is characterized by the presence of a considerable number of vendors and appears to be highly fragmented. Vendors


December 29, 2016 | 73 Pages | SKU: IRTNTR11314

Overview of the global infantile spasms therapeutics market

The global infantile spasms therapeutics market is anticipated to grow at a steady rate and will post a CAGR of above 2% during the forecast period. One of the primary drivers for this market is the growing scientific advancements in the infantile spasms therapeutic industry. Scientific advancements are helping physicians in early diagnosis, which is a crucial parameter in increasing life expectancy. Accurate diagnosis of infantile spasms can have a significant influence on the physician's decision-making process to prescribe a treatment regimen for individuals. For instance, technological advancements in medical imaging have improved the diagnosis of infantile spasms. Such scientific advantages will help in reducing the undiagnosed population, thereby raising the penetration rate of infantile spasm drugs.

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The US is the single largest regional market in the infantile spasms drugs market in the Americas. The market is expected to experience steady growth owing to the increasing number of infantile spasms patients in this region. Also, the number of patients diagnosed with infantile spasm is estimated to be nearly half of the total number of patients in the region. To reduce the number of undiagnosed cases the region is witnessing various awareness programs and initiatives. For instance, in the US, the Epilepsy Foundation of Hawaii encouraged its members to dress in purple or a day, to create awareness regarding epilepsy and its related diseases.  

Competitive landscape and key vendors

At present, the global infantile spasm therapeutics market is served by a limited number of vendors, this makes the market lucrative and provides immense growth opportunities. The


December 27, 2016 | 115 Pages | SKU: IRTNTR11278

Overview of the global cancer monoclonal antibodies (mAbs) market

Technavio’s market research analyst predicts the global cancer monoclonal antibodies (mAbs) market to grow at a CAGR of around 11% by 2021. At present, the market is witnessing the emergence of targeted and combination therapies for the treatment of cancers and inflammatory diseases. These therapies exploit the surface properties of the infected cells and cause fewer adverse side effects than the conventional non-targeted therapies. As targeting multiple pathways minimizes the threat of developing treatment-resistant disorders, combination therapies are highly preferable in treating cancers. Also, several vendors in the market are collaborating and entering strategic alliances to develop and market the novel drugs. For instance, Seattle Genetics collaborated with Bristol-Myers Squibb to launch a combination of OPDIVO and ADCETRIS to treat hematologic malignancies.

In terms of geography, the cancer mAbs market in the Americas is growing at a steady rate due to the higher acceptance of existing cancer mAbs and the introduction of new ones. Also, the region is likely to witness accelerated approvals for specific formulations and pipeline molecules, encouraging more vendors to conduct research activities in the market. Recently, the US FDA granted accelerated approval to daratumumab injection (DARZALEX) for the treatment of multiple myelomas.

Competitive landscape and key vendors

The global cancer mAbs market is marked by the presence of established vendors such as F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda


Pages